罗替高汀贴片联合多巴丝肼治疗帕金森病的临床研究

Clinical study on Rotigotine Patch combined with levodopa and benserazide hydrochloride in treatment of Parkinson’s disease

目的 探讨罗替高汀贴片联合多巴丝肼片治疗帕金森病的临床疗效。方法 选取2018年9月—2020年12月在郑州市第九人民医院就诊的108例帕金森病患者作为研究对象,按照随机数字表法将所有患者分为对照组和治疗组,每组各54例。对照组患者口服多巴丝肼片,3次/d,首次剂量0.125g/次,每周增加剂量0.125g,维持剂量3次/d,0.25g/次。治疗组患者在对照组基础上联合罗替高汀贴片,1次/d,首次剂量4.5 mg/10 cm^(2),每周增加剂量4.5 mg/10 cm^(2),维持剂量每次13.5 mg/30 cm^(2)。两组患者连续治疗3个月。观察两组患者的临床疗效,比较两组患者的生活质量、新版世界运动障碍病学会帕金森病综合评价量表(MDS-UPDRS)评分和血清因子水平。结果 治疗后,治疗组的总有效率为94.44%,对照组的总有效率为81.48%,组间比较有明显差异(P<0.05)。治疗后,两组的帕金森调查表(PDQ-39)评分显著降低(P<0.05);且治疗后治疗组PDQ-39评分低于对照组(P<0.05)。治疗后,两组的非运动症状评分、运动症状评分、运动功能检查评分、运动并发症评分均显著降低(P<0.05);治疗组的非运动症状评分、运动症状评分、运动功能检查评分、运动并发症评分明显低于对照组(P<0.05)。治疗后,两组的血清淀粉样蛋白A(SAA)、白细胞介素-12(IL-12)水平显著降低,载脂蛋白A1水平显著升高(P<0.05);治疗组SAA、IL-12水平比对照组低,载脂蛋白A1比对照组高,差异有统计学意义(P<0.05)。结论 罗替高汀贴片联合多巴丝肼片治疗帕金森病的疗效确切,能有效改善患者生活质量,减轻临床症状,减轻炎症反应。

Objective To investigate the clinical efficacy of Rotigotine Patch combined with Levodopa and Benserazide Hydrochloride Tablets in treatment of Parkinson’s disease. Methods Patients(108 cases) with Parkinson’s disease in Ninth People’s Hospital of Zhengzhou from September 2018 to December 2020 were randomly divided into control and treatment groups, and each group had 54 cases. Patients in the control group were po administered with Levodopa and Benserazide Hydrochloride Tablets, three times daily.The first dose was 0.125 g/time, the dose was increased by 0.125 g every week, and the maintenance dose was 0.25 g/time,three times daily. Patients in the treatment group were given Rotigotine Patch on the basis of the control group. The first dose was 4.5 mg/10 cm^(2), the dose was increased by 4.5 mg/10 cm^(2) every week, and the maintenance dose was 13.5 mg/30 cm^(2). Patients in two groups were treated for three months. After treatment, the clinical efficacies were evaluated, and the quality of life, the MDS-UPDRS score and the serum factor levels in two groups were compared. Results After treatment, the total effective rate of the treatment group was 94.44%, the total effective rate of the control group was 81.48%, and there was a significant difference between two groups(P <0.05). After treatment, the PDQ-39 score of two groups were significantly decreased(P < 0.05), and the PDQ-39 score of the treatment group was lower than that of the control group(P < 0.05). After treatment, the scores of non-motor symptoms, motor symptoms, motor function examination, and motor complications in two groups were significantly decreased(P < 0.05). The scores of non-motor symptoms, motor symptoms, motor function examination, and motor complications in the treatment group were significantly lower than those in the control group(P < 0.05). After treatment, the serum levels of SAA and IL-12 in two groups were significantly decreased, but the level of apolipoprotein A1 in two groups significantly increased(P < 0.05). The levels of SAA and IL-12 in the treatment group were lower than those in the control group, but the apolipoprotein A1 in the treatment group was higher than that in the control group, and the difference was statistically significant(P < 0.05). Conclusion Rotigotine Patch combined with Levodopa and Benserazide Hydrochloride Tablets in treatment of Parkinson’s disease, can effectively improve the quality of life of patients, reduce clinical symptoms and reduce inflammatory reaction.